Concepedia

Author

Ofer Shpilberg

Rabin Medical CenterORCID

Also Known As

D. Shahin, O Shpilberg, O. SHPILBERG, O. Shpilberg, OFER SHPILBERG, Ofer Shpilberg, S. Ofer, Shpilberg Ofer, Shpilberg, Ofer, Vanderson Rocha

434

Publications

22.6K

Citations

66

H-Index

181

Concepts

All Affiliations

Rabin Medical CenterTel Aviv UniversitySheba Medical CenterAssuta Medical CenterDana-Farber Cancer Institute
OS

About

Ofer Shpilberg is an author at Rabin Medical Center specializing in medicine, oncology, and pathology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

30

67

8.7K

2

Health Sciences

16

22

1K

3

Public Health

9

9

251

4

Natural Sciences

2

2

86

5

Education

1

1

17

Ofer Shpilberg

×

149

Publications

18.8K

Citations

54

H-Index

YearCitations

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

Michael Pfreundschuh, Lorenz Trümper, Anders Österborg,

The Lancet Oncology

2006

2.1K

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

Jesús F. San Miguel, Rudolf Schlag, Nuriet K. Khuageva,

New England Journal of Medicine

2008

1.9K

Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial.

B Coiffier, E.A. Osmanov, Xin Hong,

The Lancet Oncology

2011

1.6K

Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

Christian Gisselbrecht, Nicolas Mounier, Devinder Gill,

Journal of Clinical Oncology

2010

1.6K

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.

Robert H. Collins, Ofer Shpilberg, William R. Drobyski,

Journal of Clinical Oncology

1997

1.3K

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

Michael Pfreundschuh, Evelyn Kuhnt, Lorenz Trümper,

The Lancet Oncology

2011

796

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

M. Dreyling, Elı́as Campo, Olivier Hermine,

Annals of Oncology

2017

732

Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial

María‐Victoria Mateos, Paul G. Richardson, Rudolf Schlag,

Journal of Clinical Oncology

2010

431

Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study

Éric Van Den Neste, Norbert Schmitz, Nicolas Mounier,

Bone Marrow Transplantation

2015

308

Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20<sup>+</sup> Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma

Christian Gisselbrecht, Norbert Schmitz, Nicolas Mounier,

Journal of Clinical Oncology

2012

269

Page 1